Glycosyltransferases
Glycosyltransferases catalyze glycosidic bond formation using sugar donors containing a nucleoside phosphate or a lipid phosphate leaving group. Two structural folds, GT-A and GT-B, have been identified for the nucleotide sugar-dependent enzymes, but other folds are now appearing for the soluble domains of lipid phosphosugar-dependent glycosyl transferases. Donor sugar substrates are most commonly activated in the form of nucleoside diphosphate sugars (e.g., UDP Gal, GDPMan); however, nucleoside monophosphate sugars (e.g., CMP NeuAc), lipid phosphates (e.g., dolichol phosphate oligosaccharides), and unsubstituted phosphate are also used. Nucleotide sugar-dependent glycosyltransferases are often referred to as Leloir enzymes. The acceptor substrates utilized by glycosyltransferases are most commonly other sugars but can also be a lipid, protein, nucleic acid, antibiotic, or another small molecule. Glycosyl transfer most frequently occurs to the nucleophilic oxygen of a hydroxyl substituent of the acceptor. However, it can also occur to nitrogen, sulfur, and carbon nucleophiles[1].
[1] L.L. Lairson et al. Glycosyltransferases: Structures, Functions, and Mechanisms. Ann. Rev. Biochem. 2008, 77, 521-555.
Axon ID | Name | Description | From price | |
---|---|---|---|---|
2537 | 1,5-Isoquinolinediol | PARP1 inhibitor and neuroprotective agent | €50.00 | |
1496 | 3-Aminobenzamide | Competitive small molecule inhibitor of PARP | €40.00 | |
1529 | AG 014699 | PARP1 inhibitor | €60.00 | |
2241 | AZD2461 | PARP inhibitor with poor P-glycoprotein substrate qualities | €95.00 | |
1847 | CP 316819 | Glycogen Phosphorylase (GPase) inhibitor | €145.00 | |
1268 | DR 2313 | PARP inhibitor | €90.00 | |
3398 | E7449 mesylate | Potent, brain penetrable and orally bioavailable dual inhibitor of PARP1/2 and TNKS1/2 | €110.00 | |
1279 | FK 866 | NAMPT inhibitor; NAD biosysthesis inhibitor | €90.00 | |
1546 | FK 866 hydrochloride | NAMPT inhibitor | €90.00 | |
2885 | GeA-69 | Selective allosteric and cell-active PARP14 MD2 inhibitor | €95.00 | |
1566 | Iniparib | PARP inhibitor | €60.00 | |
2510 | IWR-1-endo | Inhibitor of the Wnt/β-catenin pathway strongly inhibiting TNKS1 and TNKS2 | €90.00 | |
1922 | JW 55 | Inhibitor of tankyrase (TNKS 1 and 2) | €95.00 | |
3557 | KPT-9274 | Orally bioavailable dual PAK4/NAMPT inhibitor | €130.00 | |
4179 | KU-0058948 | Potent and specific PARP1 inhibitor | €135.00 | |
2001 | KU-0058948 hydrochloride | Potent and specific PARP1 inhibitor | €135.00 | |
2759 | ME0328 | PARP3/ARTD3 inhibitor | €95.00 | |
3588 | NGI-1 | Potent and cell-permeable inhibitor of oligosaccharyltransferase | €90.00 | |
2928 | Niraparib | Potent, selective, and orally available PARP1/2 inhibitor | €90.00 | |
1370 | NU 1025 | PARP inhibitor | €80.00 | |
2599 | NVP-TNKS656 | Selective and orally active TNKS inhibitor and antagonist of Wnt pathway activity | €95.00 | |
1464 | Olaparib | PARP inhibitor | €50.00 | |
2602 | P7C3 | Proneurogenic and neuroprotective compound that activates NAMPT | €105.00 | |
3795 | PDD00017273 | First-in-class, selective and cell-active PARG inhibitor | €90.00 | |
3113 | Rucaparib camsylate | PARP1 inhibitor | €90.00 | |
3954 | SBI-797812 | Orally active NAMPT activator | €130.00 | |
2253 | STF 118804 | Highly specific, next-generation NAMPT inhibitor | €120.00 | |
2502 | Talazoparib | Potent, selective, and orally available PARP1/2 inhibitor | €90.00 | |
2369 | UPF 1069 | PARP-2 inhibitor with >26 fold selectivity over PARP1 | €75.00 | |
1593 | Veliparib | PARP inhibitor | €40.00 |